<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141301">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01992783</url>
  </required_header>
  <id_info>
    <org_study_id>umsu.rec.1392.75</org_study_id>
    <nct_id>NCT01992783</nct_id>
  </id_info>
  <brief_title>Resistant Starch, Antioxidant Status and Insulin Resistance</brief_title>
  <official_title>The Effect of Resistant Starch Supplementation on Antioxidant Status and Insulin Resistance in Overweight and Obese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urmia University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Urmia University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effects of resistant starch supplementation
      on antioxidant status and insulin resistance in overweight and obese adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Antioxidant status</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma superoxide dismutase (SOD) Plasma malondialdehyde (MDA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fasting glucose Fasting insulin Insulin resistant (HOMA-IR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Hi-maize resistant starch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13.5 g/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>13.5 g/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hi-maize resistant starch</intervention_name>
    <description>13.5 g/day</description>
    <arm_group_label>Hi-maize resistant starch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>13.5 g/day</description>
    <arm_group_label>Maltodextrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overweight and Obese men and women

          -  Age 20-50 years

        Exclusion Criteria:

          -  weight loss or gain (more than10%) over the past 6 months, or weight loss (more than
             5%) over the past 1 month

          -  pregnancy, lactation or menopause

          -  History of acute disease or clinical evidence of  cancer, acute or chronic
             inflammatory diseases, cardiovascular disease, renal disease, liver disease, thyroid
             or endocrine disease

          -  Gastrointestinal disease which ingredients found in the study products has negative
             effects on that

          -  Use of  glucose lowering, lipid lowering or anti-hypertensive medication

          -  Taking antioxidant, vitamin, and/or mineral supplements

          -  smoking
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad Alizadeh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor in Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Urmia</city>
        <state>Azerbaijan-gharbi</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 19, 2013</lastchanged_date>
  <firstreceived_date>November 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Resistant Starch</keyword>
  <keyword>Antioxidant Status</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Overweight</keyword>
  <keyword>Obesity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
